Literature DB >> 1899058

Cathepsin D concentration in breast cancer cytosols: correlation with biochemical, histological, and clinical findings.

M J Duffy1, J P Brouillet, D Reilly, E McDermott, N O'Higgins, J J Fennelly, T Maudelonde, H Rochefort.   

Abstract

Cathepsin D (CD, EC 3.4.23.5) is a lysosomal protease induced by estrogen in certain estrogen receptor (ER)-positive breast cancer cell lines but produced constitutively by ER-negative cell lines. Our aims in this investigation were to study the distribution of CD in human breast cancers and to relate its concentrations to various biochemical, histological, and clinical characteristics. The concentrations of CD were significantly higher in breast carcinomas than in either normal breast tissues or benign breast tumors. In primary carcinomas, CD concentrations did not correlate with the concentrations of ER or with the estrogen-inducible protease t-PA. However, CD concentrations did correlate weakly but significantly with both UK-PA antigen and UK-PA activity. Also, CD concentrations did not correlate with either tumor stage or axillary node status but did correlate significantly with tumor grade. Patients with cancers containing high concentrations of CD had a significantly shorter overall survival than did patients with low concentrations of the enzyme.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1899058

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  9 in total

1.  Association of ICAM-1, VCAM-1, CYCLIN D1 and Cathepsin D with Clinicopathological Parameters in Breast Carcinoma; an Immunohistochemical Study.

Authors:  Özgür Külahcı; H Hasan Esen; Elife Asut; Salim Güngör
Journal:  J Breast Health       Date:  2017-01-01

Review 2.  Evaluation of cathepsin D as a prognostic factor in breast cancer.

Authors:  P M Ravdin
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

Review 3.  Contribution of the plasma and lymph Degradome and Peptidome to the MHC Ligandome.

Authors:  Laura Santambrogio; Hans-Georg Rammensee
Journal:  Immunogenetics       Date:  2018-10-20       Impact factor: 2.846

4.  Cathepsin D in primary breast carcinoma: adverse prognosis is associated with expression of cathepsin D in stromal cells.

Authors:  A E O'Donoghue; D N Poller; J A Bell; M H Galea; C W Elston; R W Blamey; I O Ellis
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

5.  Body weight and vascular invasion in post-menopausal women with breast cancer.

Authors:  R A Badwe; I S Fentiman; R R Millis; W M Gregory
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors.

Authors:  T Jahkola; T Toivonen; K von Smitten; I Virtanen; V M Wasenius; C Blomqvist
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

7.  Cathepsin D in breast secretions from women with breast cancer.

Authors:  L M Sánchez; A A Ferrando; I Diez-Itza; F Vizoso; A Ruibal; C López-Otin
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

8.  Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours.

Authors:  D Foucré; C Bouchet; K Hacène; N Pourreau-Schneider; A Gentile; P M Martin; A Desplaces; J Oglobine
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

9.  Assay of matrix metalloproteases types 8 and 9 by ELISA in human breast cancer.

Authors:  M J Duffy; J Blaser; C Duggan; E McDermott; N O'Higgins; J J Fennelly; H Tschesche
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.